( March 14, 2025, 10:39 AM EDT) -- SAN FRANCISCO — A federal judge in California on March 13 denied as moot a motion filed by Global Blood Therapeutics Inc. (GBT) and Pfizer Inc. to dismiss a complaint alleging that Oxbryta (voxelotor), a prescription medication used for the treatment of sickle cell disease (SCD), caused a man to experience an increased rate of vaso-occlusive crises (VOCs) and to suffer a stroke after the couple filed an amended complaint....